Ornithine Decarboxylase (Decarboxylase, Ornithine)

Subscribe to Selected New Research on Ornithine Decarboxylase

1471 relevant articles (23 outcomes, 121 trials/studies) found for this Bio-Agent

Description: A pyridoxal-phosphate protein, believed to be the rate-limiting compound in the biosynthesis of polyamines. It catalyzes the decarboxylation of ornithine to form putrescine, which is then linked to a propylamine moiety of decarboxylated S-adenosylmethionine to form spermidine. EC 4.1.1.17.

Also Known As:

Decarboxylase, Ornithine; Carboxy-lyase, Ornithine; Ornithine Carboxy lyase; Ornithine Carboxy-lyase; L-Ornithine carboxy-lyase

Relationship Network

Bio-Agent Context: Research Results

Enzymes and Coenzymes: 1

Ornithine Decarboxylase: 1471

Experts

1.	Tian, Hui: 4 articles (03/2008 - 06/2006)
2.	O'Brien, Thomas G: 4 articles (10/2006 - 04/2002)
3.	Liu, Xian-Xi: 4 articles (09/2006 - 04/2003)
4.	Zhang, Yan: 4 articles (09/2006 - 04/2003)
5.	Liu, Xianxi: 3 articles (03/2008 - 01/2006)
6.	Guo, Yongjun: 3 articles (02/2004 - 04/2002)
7.	Shantz, L M: 3 articles (08/2001 - 09/2000)
8.	Feith, D J: 3 articles (08/2001 - 09/2000)
9.	Pegg, A E: 3 articles (08/2001 - 09/2000)
10.	Gilmour, Susan K: 2 articles (04/2008 - 08/2006)

Related Diseases

1.	Neoplasms (Cancer) 12/01/1994 - "However, the ornithine decarboxylase (ODC) activity in the neoplasms was significantly greater than that of the non-neoplastic and control mucosae (P < 0.001). " 01/01/2005 - "To study the mechanism of this selective effect, we used the ornithine decarboxylase (ODC)/Ras double transgenic mouse model that develops spontaneous skin tumors due to over-expression of ODC and a v-Ha-ras transgene. " 11/01/2004 - "The aim of this study is to analyze MTAP and ornithine decarboxylase (ODC) expression in primary pancreatic tumor specimens. " 07/16/1999 - "The present study was designed to determine whether 2-AP could increase the biliary excretion of metabolites of AFB(1) in rats treated with this carcinogen and whether the agent could alter the activity of ornithine decarboxylase (ODC), which is considered to be associated with tumor promotion. " 06/01/1999 - "In this study, we investigated the effect of InsP6 on 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced ornithine decarboxylase (ODC) activity, an essential event in tumor promotion in HEL-30 cells, a murine keratinocyte cell line and SENCAR mouse skin. " Order ALL the reference details at left...
2.	Starvation 04/16/1987 - "Substrate specificity in the stimulation of intestinal ornithine decarboxylase activity by refeeding after starvation." 01/01/1987 - "Increasing the duration of maternal starvation resulted in a progressive increase in fetal brain ornithine decarboxylase. " 03/30/1982 - "Induction of ornithine decarboxylase in colon and liver by starvation and refeeding: a comparison of effects on total and holoenzyme." 11/15/1980 - "In conclusion, these findings indicate that the regulation of ornithine decarboxylase in many tissues is grossly impaired in diabetes and starvation. " 11/15/1980 - "Starvation for 48h decreased ornithine decarboxylase activity to very low values in tissues of both normal and diabetic rats. " Order ALL the reference details at left...
3.	Skin Neoplasms (Skin Cancer) 01/01/2003 - "In a second experiment, two groups each consisting of three CD(1) mice were used to assess the effect of pomegranate seed oil on TPA-stimulated ornithine decarboxylase (ODC) activity, an important event in skin cancer promotion. " 04/09/2009 - "The resulting novel two-drug combination therapy targeting cellular polyamine metabolism has shown exceptional efficacy against cutaneous squamous cell carcinomas (SCC) in a transgenic ornithine decarboxylase (ODC) mouse model of skin cancer. " 10/01/2005 - "Skin cancer development is associated with increased ornithine decarboxylase (ODC) activity, DNA synthesis and rapid proliferation of epidermal cells. " 04/01/2005 - "All these processes for skin cancer development involve stimulation of DNA synthesis, DNA damage and proliferation, inflammation, immunosuppression, epidermal hyperplasia, cell cycle dysregulation, depletion of antioxidant defenses, impairment of signal transduction pathways, induction of cyclooxygenase, increase in prostaglandin synthesis, and induction of ornithine decarboxylase. " 01/01/1998 - "Therefore, the efficacy of sphingosine (SPH) and the analogs N-acetylsphingosine (NAS), N-methylsphingosine (NMS), octylamine (OCT), and sterylamine (STR) in the prevention of skin cancer was assessed in female Sencar mice by measuring effects on the induction of epidermal ornithine decarboxylase (ODC) activity and hyperplasia by 12-O-tetradecanoylphorbol-13-acetate (TPA) and effects on the induction of skin tumors by 7, 12-dimethylbenz[a]anthracene (DMBA) and TPA. " Order ALL the reference details at left...
4.	Hyperplasia 04/20/2002 - "In the present study, we found that BQ and LPA at concentrations of 25,50,75 mg/ml caused significant induction of hyperplasia, but only LPA caused an increase of epidermal ornithine decarboxylase (ODC). " 01/01/1994 - "Results from several studies have demonstrated that both ornithine decarboxylase (ODC) and DAO activity rise during adaptive hyperplasia seen after small bowel resection. " 06/01/1991 - "This study was undertaken to determine if inhibition of ornithine decarboxylase (ODC), the rate-limiting enzyme of polyamine synthesis, suppresses formation of intimal hyperplasia (IH) after arterial injury. " 09/01/1999 - "Type I diabetes is associated with jejunal mucosal hyperplasia, and administration of diflouromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase (ODC), causes hypoplasia. " 02/01/1998 - "Administration of DFMO, an irreversible inhibitor of the proliferation-associated enzyme ornithine decarboxylase (ODC), prevented diabetes-I induced jejunal hyperplasia and decreased all of the above enzymic parameters in both diabetic and control rats. " Order ALL the reference details at left...
5.	Colonic Neoplasms (Colon Cancer) 11/30/1989 - "Our previous studies have shown that generalized polyamine depletion of the human colon cancer cell line COLO 320 by 2-difluoromethylornithine is associated with decreased transcription of the c-myc, c-fos, and ornithine decarboxylase (ODC) genes. " 04/01/1994 - "Ornithine decarboxylase (ODC) is used as an early marker for colon cancer development. " 06/14/1991 - "Systemic alterations in ornithine decarboxylase activity caused by colon cancer in mice." 02/20/1991 - "Involvement of ornithine decarboxylase in the control of proliferation of the HT29 human colon cancer cell line. " 01/01/1990 - "Increased levels of phorbin, c-myc, and ornithine decarboxylase RNAs in human colon cancer." Order ALL the reference details at left...

Related Drugs and Biologics

1.	Eflornithine (Ornidyl)
2.	Putrescine
3.	Spermidine
4.	Adenosylmethionine Decarboxylase
5.	DNA (Deoxyribonucleic Acid)
6.	anthracene
7.	9,10-Dimethyl-1,2-benzanthracene (DMBA)
8.	Dinoprostone (PGE2)
9.	sodium arsenite
10.	Testosterone (Sustanon)

Related Therapies and Procedures

1.	Chemoprevention
2.	Oral Administration
3.	Drug Therapy (Chemotherapy)
4.	Ovariectomy (Oophorectomy)
5.	Hepatectomy

Best Treatments:
Research Summary Report
on Neoplasms

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 20112 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>